Rigel To Present At The 43Rd Annual J.P. Morgan Healthcare Conference
(MENAFN- PR Newswire)
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals,
Inc. (Nasdaq: RIGL ), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare conference on Thursday, January 16, 2025 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at . Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit
.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
[email protected]
Media:
David Rosen
Argot Partners
646.461.6387
[email protected]
SOURCE Rigel Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN08012025003732001241ID1109068465
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.